Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice

NCT07215767

Status	RECRUITING
Phase	Phase 3
Sponsor	HALEON
Enrollment	850 participants

Key Eligibility Criteria

Inclusion (6)

- Provision of signed and dated informed consent document (and assent document, if appropriate)
- Participant is biologically male or female.
- Participant is 12 to 65 years of age, inclusive, at the time of signing the consent/assent form.
- Participant is in good general, oral and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant or relevant abnormalities in self-reported medical history, or upon oral examination, that would impact their safety or well-being, or the outcomes of the study, if they were to participate in the study, or affect their ability to understand and follow study requirements.
- Participant has a history of tooth sensitivity lasting more than six months but not more than 10 years (self-reported).

... and 1 more (see full listing online)

Exclusion (15)

- Female participant who is pregnant at Screening and Baseline, or is intending to become pregnant during the study.
- Female participant who is breastfeeding.
- Participant with known or suspected intolerance or hypersensitivity to any of the study products, any of their stated ingredients or closely related compounds.
- Participant is participating in, or has participated in, other studies (including non-medicinal studies) involving an Investigational Product within 30 days of Screening or plans to participate in other studies (including non-medicinal studies) during this study.
- Participant has participated in a tooth sensitivity study within 8 weeks of Screening.

... and 10 more (see full listing online)

Locations (3 total)

All Sum Research Limited, Melbourne, Florida, United States
Salus Research, Inc., Fort Wayne, Indiana, United States
Silverstone Research, Las Vegas, Nevada, United States